Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Gains from Sales and Divestitures: 2024-2025

Historic Gains from Sales and Divestitures for 4D Molecular Therapeutics (FDMT) over the last 2 years, with Sep 2025 value amounting to $113,785.

  • 4D Molecular Therapeutics' Gains from Sales and Divestitures rose 249.59% to $113,785 in Q3 2025 from the same period last year, while for Sep 2025 it was $113,785, marking a year-over-year increase of 249.59%. This contributed to the annual value of $52,884 for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Gains from Sales and Divestitures is $113,785, which was up 61.91% from $70,278 recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Gains from Sales and Divestitures registered a high of $113,785 during Q3 2025, and its lowest value of $10,996 during Q1 2024.
  • For the 2-year period, 4D Molecular Therapeutics' Gains from Sales and Divestitures averaged around $46,384, with its median value being $32,548 (2024).
  • Data for 4D Molecular Therapeutics' Gains from Sales and Divestitures shows a peak YoY spiked of 249.59% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows 4D Molecular Therapeutics' Gains from Sales and Divestitures stood at $52,884 in 2024, then surged by 249.59% to $113,785 in 2025.
  • Its last three reported values are $113,785 in Q3 2025, $70,278 for Q2 2025, and $22,235 during Q1 2025.